Breast Cancer

National networks create online report to educate breast cancer patients on HER2 testing

Published in Medical Device Business Week, February 7th, 2007

The National Comprehensive Cancer Network (NCCN) and Research Advocacy Network have created an online report to educate breast cancer patients about the significance and importance of HER2 testing. Results of this test are essential in determining the correct treatment plan for breast cancer patients.

Breast cancers can be categorized as HER2 positive or HER2 negative. HER2-positive breast cancer grows more quickly and is considered more aggressive. While studies indicate that trastuzumab (Herceptin from Genentech) is effective in the treatment of HER2-positive early stage breast cancer and HER2-positive metastatic breast cancer, the drug is not effective in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Business Week

Source: Medical Device Business Week (2007-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry